Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778701 | 0.90 | TLR7 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL6777774 | 0.88 | TLR7 (0.41) | TLR7TLR8NUDT1 | |
| SCHEMBL6094643 | 0.86 | TLR7 (0.49) | TLR7TLR8NUDT1 | |
| SCHEMBL6778782 | 0.86 | TLR7 (0.44) | TLR7TLR8NUDT1 | |
| SCHEMBL6782966 | 0.86 | TLR7 (0.39) | TLR7TLR8NUDT1 | |
| SCHEMBL6288244 | 0.83 | TLR7 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL6094673 | 0.83 | TLR7 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL6768601 | 0.83 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL6776452 | 0.83 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| SCHEMBL6775573 | 0.82 | TLR7 (0.39) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923560-B2 | Associated with typically attached to and, preferably, covalently attached to macromolecular support, e.g. a gel, foam, sponge, fiber, hydrogel, and a bead.; controlled drug delivery; retension of localized biological activity; toll-like receptors agonists to induce cytokine and interferon synthesis | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923560-B2 | Associated with typically attached to and, preferably, covalently attached to macromolecular support, e.g. a gel, foam, sponge, fiber, hydrogel, and a bead.; controlled drug delivery; retension of localized biological activity; toll-like receptors agonists to induce cytokine and interferon synthesis | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1617871-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING METAL-CONTAINING PARTICULATE SUPPORT MATERIALS | 3M Innovative Properties Company (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1615665-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M Innovative Properties Company (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040258698-A1 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-23 | — | — | US | disclosed |
| WO-2004108072-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING METAL-CONTAINING PARTICULATE SUPPORT MATERIALS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004091500-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258698-A1 | Delivery of immune response modifier compounds | MIF, IRF3, CLEC4M | TLR7 126/4885TLR8 51/4885NUDT1 4064/4885 |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | MIF, IRF3, IRF2BP2 | TLR7 131/4885TLR8 99/4885NUDT1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.